[HTML][HTML] αIIbβ3 priming and clustering by orally active and intravenous integrin antagonists
RR Hantgan, MC Stahle, JH Connor, RF Connor… - Journal of Thrombosis …, 2007 - Elsevier
Background: Drugs that block platelet–platelet and platelet–fibrin interactions via the α IIb β
3 (glycoprotein IIb/IIIa) receptor are used daily in patients undergoing percutaneous
coronary interventions. Along with expected increases in spontaneous bleeding, clinical
trials have revealed a surprising increase in thrombosis when these drugs are used without
other anticoagulants. A better understanding of their mechanisms can minimize these risks.
Objectives: This study tested the hypothesis that interventions designed to block fibrinogen …
3 (glycoprotein IIb/IIIa) receptor are used daily in patients undergoing percutaneous
coronary interventions. Along with expected increases in spontaneous bleeding, clinical
trials have revealed a surprising increase in thrombosis when these drugs are used without
other anticoagulants. A better understanding of their mechanisms can minimize these risks.
Objectives: This study tested the hypothesis that interventions designed to block fibrinogen …